Previous Article | Next Article 
Mol Cell Biol, April 1998, p. 2184-2195, Vol. 18, No. 4
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Characterization of BCE-1, a Transcriptional Enhancer
Regulated by Prolactin and Extracellular Matrix and Modulated by
the State of Histone Acetylation
Connie A.
Myers,1
Christian
Schmidhauser,2
Julia
Mellentin-Michelotti,3
Gilberto
Fragoso,3
Calvin D.
Roskelley,1
Gerald
Casperson,4
Romina
Mossi,5
Philippe
Pujuguet,1
Gordon
Hager,3 and
Mina J.
Bissell1,*
Life Sciences Division, Berkeley National Laboratory,
Berkeley, California 947201;
Voltastrasse 39, 8044 Zürich,
Switzerland2;
Laboratory of Receptor
Biology and Gene Expression, National Cancer Institute, National
Institutes of Health, Bethesda, Maryland
208923;
Searle Research
Division/Monsanto Company, Chesterfield, Missouri
630174; and
Institute for
Veterinarian Biochemistry, University of Zürich (Irchel), 8057 Zürich, Switzerland5
Received 3 April 1997/Returned for modification 27 April
1997/Accepted 16 December 1997
 |
ABSTRACT |
We have previously described a 160-bp enhancer (BCE-1) in the
bovine
-casein gene that is activated in the presence of prolactin and extracellular matrix (ECM). Here we report the characterization of
the enhancer by deletion and site-directed mutagenesis, electrophoretic mobility shift analysis, and in vivo footprinting. Two essential regions were identified by analysis of mutant constructions: one binds
C/EBP-
and the other binds MGF/STAT5 and an as-yet-unidentified binding protein. However, no qualitative or quantitative differences in
the binding of these proteins were observed in electrophoretic mobility
shift analysis using nuclear extracts derived from cells cultured in
the presence or absence of ECM with or without prolactin, indicating
that prolactin- and ECM-induced transcription was not dependent on the
availability of these factors in the functional cell lines employed. An
in vivo footprinting analysis of the factors bound to nuclear chromatin
in the presence or absence of ECM and/or prolactin found no differences
in the binding of C/EBP-
but did not provide definitive results for
the other factors. Neither ECM nor prolactin activated BCE-1 in
transient transfections, suggesting that the chromosomal structure of
the integrated template may be required for ECM-induced transcription.
Further evidence is that treatment of cells with inhibitors of histone
deacetylase was sufficient to induce transcription of integrated BCE-1
in the absence of ECM. Together, these results suggest that the ECM induces a complex interaction between the enhancer-bound transcription factors, the basal transcriptional machinery, and a chromosomally integrated template responsive to the acetylation state of the histones.
 |
INTRODUCTION |
It is now well established that the
processes of development and differentiation depend on a cell's
ability to correctly perceive its microenvironment (reviewed in
references 1 and 43). A key
component of this environment is the extracellular matrix (ECM). The
ECM is an organized network of glycoproteins, proteoglycans, and
glycosaminoglycans, components important for cell morphology as well as
for signal transduction via cell surface integrins and ultimately for
tissue-specific gene expression (reviewed in reference
43).
The mammary gland appears to be particularly well suited for the study
of ECM-induced differentiation and gene expression. In the adult
animal, the gland develops after puberty and functionally differentiates in response to pregnancy. The mechanisms involved in
these developmental processes are complex and guided by various hormones (54), growth factors (53), and the ECM
(3). Milk protein expression is initiated at mid-pregnancy
and correlates with the synthesis and deposition of a specialized
laminin-rich ECM during alveolar development. Expression of these milk
proteins can be used as markers for the differentiated state of the
gland. In the last decade, a number of model systems using mammary
epithelial cells to study ECM-dependent gene regulation have been
developed. These range from primary cultures to cloned cell lines which
undergo a three-dimensional reorganization in gelatinous matrices to
form alveolus-like structures capable of synthesizing and vectorially secreting milk proteins, analogous to their in vivo counterparts in the
lactating mammary gland (references 2 and
30 and references therein).
Studies with SCP2 (11) and CID-9 (44) cell lines
derived from the COMMA 1D cell strain (8), itself derived
from the mammary tissue of midpregnancy mice, have shown that induction of endogenous
-casein requires both an ECM-induced change in cell shape and a
1-integrin-mediated biochemical signaling by laminin, a major component of mammary basement membrane (42, 52). Downstream nuclear events associated with this integrin signal transduction pathway have been analyzed with stable
transfectants of CID-9 cells with the bovine
-casein promoter linked
to the chloramphenicol acetyltransferase (CAT) reporter gene. These
studies clearly demonstrated that the transcriptional regulation of
this gene is dependent on the presence of both ECM and lactogenic
hormones (44). Deletion analysis of this promoter identified
a 160-bp transcriptional enhancer (BCE-1) capable of conferring ECM and hormonal regulation in either orientation to the inactive proximal
-casein promoter (
121 to +42) (46).
Many cis-acting transcription elements have been identified
in the rat and mouse
-casein genes. Their functional role in induction of transcription has been studied in mammary glands of
transgenic animals, in primary mammary epithelial cells, and in other
cell lines such as HC11 (also derived from COMMA 1D) (14, 19, 29,
63). These studies have identified three major
trans-acting factors that are involved in the
hormone-induced transcriptional activation of
-casein. Prolactin has
been shown to activate transcription via STAT5, originally identified
as mammary gland factor (MGF) (20, 47, 56, 57-59). STAT5
binding sites are found in many other milk protein promoters, with the STAT binding sites in the sheep
-lactoglobulin gene being
particularly well characterized (5, 6, 51, 58). C/EBP
binding sites are required for the hormonal induction of
-casein
expression (16, 41, 49), and its activity may be influenced
by glucocorticoid receptor, which has been shown to enhance
prolactin-induced expression of
-casein (15, 25, 41, 44,
50).
In this study, we found that the binding sites for C/EBP and STAT5 are
contained within the ECM-responsive element BCE-1. Furthermore, we show
that these elements, as well as an unidentified binding protein (UBP)
site are critical for ECM and prolactin responsiveness. Unexpectedly,
we also find that despite the dramatic increase in transcription when
the cells are cultured on ECM, these factors appear to be bound to
BCE-1 even when cells are cultured on plastic in the absence of
prolactin. Based on the induction of BCE-1 transcriptional activity in
cells cultured on plastic after treatment with histone deacetylase
inhibitors, we propose that the ECM may allow transcription of the
-casein gene via a mechanism that involves modulation of histone
acetylation.
 |
MATERIALS AND METHODS |
Plasmids. (i) Cloning of the deletions.
The first 100 bp and
the 3' 61 bp of BCE-1 were isolated by PCR from the expression plasmid
BBC (termed BCE-1/ER-1/CAT in reference 46).
These fragments were cloned into ER-1 and checked by sequencing.
(ii) Site-specific mutations.
Site-specific mutations were
introduced into BBC with a mutagenesis kit (transformer site-directed
mutagenesis kit; Clontech, Palo Alto, Calif.). The 30-bp primers for
mutagenesis included 10 bp of BCE-1 sequence flanking the mutation
sequence GCTCTAGAGC (an XbaI site
[underlined] flanked by GCs). The correct introduction of each
mutation was confirmed by sequencing.
(iii) Plasmids for transient transfections.
MMTV/CAT,
MMTV/
-cas/CAT, and SV40/
-cas/CAT were described previously
(45); LTR/Luc is described in reference
31.
Cell passage and differentiation.
CID-9 cells
(44) and their transfected derivatives were passaged in
Dulbecco modified Eagle medium (DMEM)-F-12-5% fetal calf
serum-insulin (5 µg/ml) (referred to as growth medium) and induced
to differentiate in DMEM-F-12-insulin (I) (5 µg/ml) without or with
1 µg of hydrocortisone (H) per ml and/or 3 µg of prolactin per ml
(P) as described previously (differentiation medium
[46]). Sodium butyrate (Sigma Chemical Co., St. Louis,
Mo.) and trichostatin A (Wako Pure Chemical Industry, Richmond, Va.)
were prepared as 1,000× stock solutions in water and ethanol,
respectively. In experiments where sodium butyrate and trichostatin A
were used, the cells were treated 48 h after plating and harvested
after 18 h of treatment. In some of the experiments, Matrigel
(Collaborative Biomedical Products, Bedford, Mass.), insulin
(Gibco/BRL, Bethesda, Md.), and prolactin (Sigma) were used. Stable
transfections, cell harvest, and CAT assays were performed as described
previously (46).
Transient transfections.
CID-9 cells were plated in growth
medium at a density of 3 × 105 per 60-mm-diameter
tissue culture plastic dish or at 1.2 × 106 per 60-mm
dish in dishes coated with 0.4 mg of polyhema (Sigma [42]) 1 day prior to transfection. Cells were given
DMEM-5% fetal calf serum and 5 µg of insulin per ml at least 3 h before transfection. Ten micrograms of test plasmid and 1 µg of
RSV/
gal were cotransfected by the calcium phosphate method
(46) with the exception that the precipitates were left on
the cells for 18 h. The cells were then washed three times with
DMEM-F-12 and placed in differentiation medium (IHP). Cells cultured
on polyhema were given differentiation medium containing 2% Matrigel as described previously (42). They were harvested 48 h
later with Dispase (44). Lysates were assayed for
-galactosidase (
-Gal) activity (Glacto-Light; Tropix, Bedford,
Mass.), protein content (Bio-Rad protein assay; Bio-Rad, Hercules,
Calif.), and CAT (44) or luciferase activity
(12). The thin-layer chromatography (TLC) plates from the
CAT assays were exposed to PhosphorImager screens and analyzed with a
Molecular Dynamics PhosphorImager. The CAT activity was analyzed and
expressed relative to
-Gal activity.
Preparation of nuclear extracts.
Nuclear proteins for
electrophoretic mobility shift analysis (EMSA) were extracted by two
different procedures (10, 48) with similar results in the
quality and quantity of the isolated proteins. Extracts were isolated
in the presence or absence of the phosphatase inhibitors sodium
fluoride, sodium molybdate, and orthovanadate. Cells cultured on ECM
were released by Dispase treatment or harvested by matrix dissolution
with phosphate-buffered saline (PBS) (without calcium and magnesium), 5 mM EDTA, and protease inhibitors (0.5 mM phenylmethylsulfonyl fluoride,
0.5 mM dithiothreitol, 2 mM benzamidine, 5 µg each of pepstatin and
leupeptin per ml) (a kind gift of Steve Farmer, Boston University) or
harvested by scraping cells together with the ECM (isolation conditions were as noted in the figure legends). All extracts were quantitated for
protein (Bio-Rad), and aliquots were run on sodium dodecyl sulfate
(SDS)-12% polyacrylamide gel electrophoresis and visualized by
Coomassie blue staining to assess the quality and to independently quantitate the extracts. With the exception of slight ECM contamination in extracts isolated from cells which did not have the ECM removed by
Dispase or PBS dissolution, the methods produced similar results in all
BCE-1 EMSAs. However, Dispase-treated nuclear extracts displayed an
altered NF-1 mobility shift (34a), indicating that these
preparative methods may not be equivalent for all nuclear proteins.
EMSA.
Mobility shift probes were labeled as single-stranded
oligonucleotides with T4 polynucleotide kinase in the presence of
[
-32P]ATP (>5,000 Ci/mmol); complementary strands
were annealed, and the double-stranded probe was gel purified. The
amount of labeled probe ranged from 10 to 60 fmol per binding assay.
The sequences below represent the coding strands for the following
oligonucleotides: A, 5'-TGTATTCCTTTTCTCAGAAATC; B,
5'-ATCACACTTTTTTGCCTGTGGC; D, 5'-CTGTTTATTGCACAATATGT;
C/EBP, 5'-TGCAGATTGCGCAATCTGCA (7); and
MGF, 5'-GGACTTCTTGGAATTAAGGGA (adapted from reference
47).
Nuclear proteins (10 µg) were incubated for 20 min in binding buffer
(20 mM HEPES [pH 7.8], 0.5 mM MgCl2, 1 mM dithiothreitol, 0.5 mM EDTA, 5% glycerol, 80 mM NaCl) with 0.5 µg of poly(dI-dC) and
10,000 cpm of probe in a 20-µl volume. Binding reactions were run on
a 5% nondenaturing polyacrylamide gel in 0.25× Tris-borate-EDTA. When
present, competitors were double stranded and used at a 50-fold molar
excess over the labeled probe. For supershift analysis, antibodies
against C/EBP-
, -
, and
and CRP1 were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, Calif.), and those against STAT5a and
STAT5b (a kind gift of Lothar Henninghausen, National Institutes of
Health) and STAT1 and STAT3 were obtained from Transduction
Laboratories Inc. (Lexington, Ky.). The binding reactions were carried
out for 20 min at room temperature, and then antibodies were added and
the reaction mixtures were set on ice for 30 min before being loaded
onto a 4% acrylamide-0.25× Tris-borate-EDTA gel.
Nucleus isolation and exonuclease assay.
Nuclei were
isolated from cells as described previously (39), with the
exception that cells cultured on ECM were first released by the PBS
treatment described above. The digestion of nuclei for exonuclease
assays was similar to that of Pennie et al. (39). An aliquot
of each nucleus preparation was quantitated for DNA content. Nuclei
were thawed on ice and diluted into Workman and Langmore buffer (50 mM
NaCl, 50 mM Tris-Cl [pH 8], 0.5 mM MgCl2, 1 mM
beta-mercaptoethanol) such that 200-µl aliquots contained 20 µg of
DNA. The nuclease digestions were conducted for 15 min at 37°C with
the following nuclease concentrations (per microgram of DNA):
HinfI, NcoI, and BamHI, 20 U; lambda
exonuclease, 1 U; and T7 exonuclease, 50 U. The reactions were stopped
by adding an equal volume of stop solution (0.2 M NaCl, 50 mM Tris-Cl
[pH 8], 20 mM EDTA, 2% SDS). Protease K (10 µl of a 10-mg/ml
solution) was added, and the samples were incubated at 37°C
overnight. The samples were then extracted with phenol-chloroform and
precipitated with 0.25 M NaCl and isopropanol. Washed pellets were
dried and resuspended in water prior to a secondary restriction
digestion, which was performed with the following enzymes:
StyI or EcoRI for HinfI,
BstBI for NcoI, and BsRI for
BamHI (2 to 4 U/µg of DNA). Samples were extracted and
precipitated as described above. Ten-microgram portions of each sample
were subjected to linear amplification with
[
-32P]ATP-labeled oligonucleotides and Taq
polymerase. Samples were extracted as described above and precipitated
with 0.25 M NaCl and ethanol, resuspended in 80% formamide solution
containing bromophenol blue and xylene cyanol, and separated on an 8%
denaturing polyacrylamide gel. Dried gels were exposed to a
PhosphorImager screen and analyzed with a Molecular Dynamics
PhosphorImager. Twenty nanograms of BBC plasmid DNA was subjected to
the same treatment described above as a control for primary enzyme
cutting and primer extension in the PCR step. Genomic DNA isolated from stably BBC-transfected CID-9 cells was used as a control to demonstrate the ability of lambda and T7 exonuclease to progress through the genomic sequence of BBC. The digestion with the secondary enzyme allows
for visualization of the quantity of DNA present in each condition.
 |
RESULTS |
Functional elements within BCE-1.
A deletion analysis was
first conducted to characterize the functionally important regions
within the 160-bp BCE-1 enhancer. Two deletion constructs were made,
one containing 100 bp of 5' end and one containing 60 bp of the 3' end
of the BCE-1 enhancer linked to the transcriptionally inactive
121 to
+42 sequence of the bovine
-casein promoter (Fig.
1A). The constructs were stably
transfected into CID-9 cells, and the activity of each was compared to
that of stably integrated full-length BCE-1. Neither deletion construct
was active, in either the presence or absence of ECM (Fig. 1A and data
not shown). Therefore, BCE-1 requires the presence of both halves for
transcriptional activity. A more detailed mutational analysis was then
conducted with linker mutant constructs. Mutations were generated
across BCE-1 by the replacement of sequential 10-bp stretches of DNA
with an XbaI linker. These constructs were stably
transfected into CID-9 cells, and transcriptional activity was assessed
in the presence or absence of ECM and/or lactogenic hormones. In the
presence of ECM and prolactin five mutations resulted in a loss of at
least 90% activity compared to wild-type BCE-1 (Fig. 1B). These
mutations were localized to two separate regions within BCE-1. Mu3 and
Mu4 lay within the first 100 bp of BCE-1 and span a putative C/EBP
binding site (region I). Mu11, Mu12, and Mu13 were in the last 60 bp
and include a putative STAT5 binding site and another potential protein
binding site (region II) (Fig. 1C). All other mutant constructs had
between 30 and 80% of wild-type activity. As found with wild-type
BCE-1, none of the mutants activated transcription in the absence of ECM and/or lactogenic hormones (data not shown).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 1.
Identification of two functional regions of BCE-1. (A)
Schematic representation of full-length BCE-1 (BBC) and two deletion
constructs (60 and 100) linked to the minimal bovine -casein
promoter. Sequences are numbered relative to the transcription start
site of the endogenous gene. The chart on the right summarizes the
transcription activity of the three constructs stably transfected into
CID-9 cells. The cells were cultured under differentiation conditions
(IHP) without (plastic) or with ECM for 6 days and assayed for CAT
activity. , no detectable activity; +, increasing amounts of
transcriptional activity. (B) Transcriptional activity of 15 mutant
constructions spanning the entire wild-type BCE-1 enhancer stably
transfected into CID-9 cells. Each mutation was generated by
replacement of 10 bp of BCE-1 sequence with GCTCTAGAGC
(an XbaI site [underlined] flanked by GCs) as
described in Materials and Methods. Cells were cultured in IHP on ECM
for 6 days and assayed for CAT activity. The graph shows the average of
at least three separate transfections for each mutation (Mu1 to Mu15)
and shows each mutant's activity as a percentage of the wild-type
BCE-1 (WT) transfected and differentiated at the same time as the
mutants. (C) Sequence of the wild-type BCE-1 enhancer and the locations
of mutations (Mu1 to Mu15). Regions I and II show the sequence in which
mutations knocked out most of the transcriptional activity. The
consensus sequence for putative binding sites of C/EBP and STAT are
given (uppercase letters denote exact base pair matches). UBP
represents a potential protein binding site.
|
|
Identification of BCE-1 binding activities by EMSA (i) C/EBP-
binds to region I.
Nuclear extracts from exponentially growing
CID-9 cells or CID-9 cells cultured in the presence or absence of ECM
and/or lactogenic hormones formed specific complexes with a 20-bp
oligonucleotide (oligonucleotide D) that spanned region I, which
contains the putative C/EBP binding site. These complexes were competed
by an excess of either cold oligonucleotide D (Fig.
2A, "+" lanes; Fig. 2B, lane 4) or a
consensus oligonucleotide to C/EBP (Fig. 2B, lanes 5 and 6). There was
no difference in the ability to form a complex whether extracts were
isolated from (i) actively dividing cells in the presence of serum and
the absence of lactogenic hormones (growth), (ii) growth-arrested cells
in the absence of serum and the presence of lactogenic hormones
(plastic), or (iii) growth-arrested cells in the presence of lactogenic
hormones and exogenous basement membrane (i.e., the ECM). The region I
complex was supershifted upon incubation with an antibody to C/EBP-
(Fig. 2C, lane 4) but not by an antibody to C/EBP
, C/EBP
, or CRPI (a C/EBP homolog) (Fig. 2C, lanes 3, 5, and 6). Nuclear extracts from
the liver, which is known to be an abundant source of C/EBP-
and
-
, formed specific complexes with oligonucleotide D (Fig. 2B, lanes
8 to 10) which could be supershifted by both the C/EBP-
and -
antibodies (Fig. 2C, lanes 9 and 10).

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 2.
Characterization of the binding activities of proteins
interacting with regions I. A schematic of BCE-1 showing the relative
positions of oligonucleotides A, B, and D is shown at the top. The
C/EBP consensus oligonucleotide is represented by a dashed line above
region I. The nuclear extracts isolated from CID-9 cells are designated
as follows: G, actively growing cells; P, cells cultured in
differentiation medium (IHP); E, cells cultured on ECM in
differentiation medium. E(d) cells were harvested with
Dispase; E(p) cells were harvested by PBS dissolution.
Extracts in A, B, and C were isolated as described previously
(references 10 and 48,
respectively). Liver extracts were isolated from mouse liver as
described previously (48). (A) EMSA using oligonucleotide D. The "+" indicates that a 50× molar excess of unlabeled
double-stranded oligonucleotide D was added to the binding mixture. The
first lane is labeled probe without extract. (B) EMSA comparing the
binding activity of CID-9 cell extracts to that of mouse liver. The
competitions are shown below the gel as follows: , no competitor;
oligonucleotide D (50×); consensus C/EBP (50× and 500×), 50×
poly(dI-dC) (nonspecific competitor). The last lane is labeled probe
without extract. (C) EMSA using oligonucleotide D with CID-9 extracts
from cells cultured on ECM in IHP and extracts from mouse liver. The
first lane is labeled probe with no extract; , , , and CRPI
represent binding reactions incubated with antibodies to C/EBP- ,
- , and - and to CRPI (as described in Materials and Methods). The
CID-9 cell extracts are supershifted only with an antibody to
C/EBP- , and the liver extracts are supershifted with antibodies to
C/EBP- and - .
|
|
(ii) Region II binds STAT protein and an additional unidentified
binding protein (UBP).
An oligonucleotide that spans the putative
STAT5 binding site in BCE-1 (oligonucleotide A) (Fig.
3A) formed specific complexes with either
actively growing CID-9 nuclear extracts or CID-9 cells cultured in the
presence or absence of ECM. These complexes were competed by an excess
of unlabeled oligonucleotide A (Fig. 3A, "+" lanes) or an
oligonucleotide to the rat MGF/STAT5 binding site but not by an
oligonucleotide to region II which lies outside the STAT site
(oligonucleotide B) (data not shown). Supershift analysis of
oligonucleotide A with antibodies to STAT5, STAT1, and STAT3 revealed
that STAT5 is present in nuclear extracts from cells cultured on
plastic and ECM (Fig. 3B). Regardless of the culture conditions, there
were no differences in the binding activity present in the various
nuclear extracts. This included cells cultured with or without
lactogenic hormones.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 3.
Characterization of the binding activities of proteins
interacting with region II. The schematic and the extracts isolated
were as described for Fig. 2. (A) EMSA using oligonucleotide A from
region II as a probe with nuclear extracts from CID-9 cells as
described for Fig. 2. +, lanes with a 50× molar excess of unlabeled
double-stranded oligonucleotide A. (B) EMSA using oligonucleotide A
with nuclear extracts from CID-9 cells cultured on plastic in IHP and
ECM in IHP. , no antibody; 5, addition of 1 µl of a 1:10 dilution
of a 1:1 mixture of STAT5a and STAT5b antibodies to the binding
reaction; 1 and 3, addition of 1 µl of antibody to STAT1 and STAT3,
respectively. (C) EMSA using oligonucleotide B from region II as a
probe. +, a 50× molar excess of unlabeled double-stranded
oligonucleotide B (the quantitative differences in binding activity
observed in this gel varied in at least three different EMSAs).
|
|
Oligonucleotide B, which spans the 3' end of region II, also formed a
specific complex (Fig.
3C). This complex could be competed
by an excess
of unlabeled oligonucleotide B (Fig.
3C, "+" lanes)
but not by
oligonucleotide A or an oligonucleotide that contains
the Mu13 mutation
(data not shown). Although there are differences
in the intensities of
some complexes among nuclear extracts from
cells cultured under
different conditions, these differences were
not consistent from assay
to assay with either the same or independently
isolated nuclear extract
preparations. Therefore, no definitive
conclusions can be drawn by the
relative intensities. However,
the binding activities and their
sensitivity to competition were
always consistent among extracts and
different preparations.
The ability of nuclear proteins to bind to oligonucleotides in in vitro
binding assays does not guarantee that these same
proteins will have
the access and/or the ability to bind to a
chromatin template. We
therefore examined whether the factors
were differentially bound on the
intact chromatin template in
cells cultured with or without ECM and/or
prolactin.
The ECM does not appear to restrict or induce factor loading
onto the chromatin template.
In order to determine whether
ECM-dependent transcription results from changes in factor access to
the chromatin template, we conducted in vivo exonuclease footprinting
analyses. We examined factors bound to chromatin in nuclei isolated
from BBC-transfected CID-9 cells which were cultured with or without
ECM and/or prolactin, leading to conditions of active and inactive
transcription, respectively. To ascertain the transcriptional state of
the cells, we routinely performed CAT assays using an aliquot of cells
taken before the nuclei were isolated (Fig.
4A). To analyze region I (Fig. 4C), nuclei were treated with the restriction enzyme NcoI with or
without the exonuclease lambda or T7. The exonuclease stops were within the boundaries of the C/EBP and OctI binding sites. However, no differences in the stop patterns were observed under any of the culture
conditions tested. A number of control reactions were conducted to
confirm the specificity of the exonuclease stops. Genomic DNA isolated
from the stably transfected CID-9 cells was used as a control for DNA
sequence-induced stops (Fig. 4B). BBC plasmid was used as a control for
the ability of the restriction enzyme to cut under the digestion
conditions used, as well as a control for possible pausing during the
PCR primer extension analysis. In addition, two different exonucleases
(lambda and T7) were used, since they have different abilities to
penetrate DNA that contains bound protein. The control reactions show
that the stops are not due either to sequence-dependent pausing by the
exonuclease or to peculiarities specific to one nuclease.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 4.
Exonuclease analysis of BCE-1 shows identical stop
patterns for both the active and inactive states of the promoter for
C/EBP. (A) Diagram of the BBC construct identifying the primary and
secondary enzyme digestion sites and the relative location of the
primers. Corresponding CAT assays of lysates collected from an aliquot
of cells from each culture condition prior to nucleus isolation. The
cells cultured on ECM were isolated by PBS dissolution. P, plastic; i,
insulin; h, hydrocortisone; p, prolactin; E, ECM. (B) Exonuclease
control for genomically induced pausing of the lambda and T7
exonucleases. Genomic DNA isolated from stably BBC-transfected CID-9
cells was cut with NcoI, and aliquots were treated with
increasing amounts of exonuclease for 15 min at 37°C. DNA was
purified and subjected to primer extension using labeled primer 3A.
Lanes: 1 and 2, BBC plasmid DNA extended with labeled primer 3A
incorporating ddGTP and ddATP, respectively; 3 to 6, 0.5, 1, 2.5, and 5 U of lambda exonuclease per µg of genomic DNA; 7, control (no
exonuclease); 8 to 10, 5, 10, and 25 U of T7 exonuclease per µg of
genomic DNA. (C) Exonuclease analysis of region I. NcoI was
used to open the chromatin DNA for exonuclease entry. The secondary
enzyme was BstBI, and primer extensions were performed with
oligonucleotide 3'A. Major stops are designated by arrows 1 to 4, and
their positions within the BCE-1 sequence are noted beside the arrows.
The positions of the consensus sequences for C/EBP and OctI are noted
below the figure.
|
|
We have shown by EMSA that OctI forms a specific complex with an
oligonucleotide corresponding to the sequence of the wild-type
Mu5
region of BCE-1, which can be competed by an excess of unlabeled
oligonucleotide as well as by an OctI consensus oligonucleotide
(data
not shown). However, since there was no significant decrease
in
transcriptional activity when this site was mutated, we believe
that
OctI modulation of ECM-dependent transcriptional activation
is not
absolutely required. The footprinting results were consistent
with the
OctI site being occupied in vivo.
Region II of BCE-1 was analyzed with the restriction enzyme
HinfI to open the chromatin. Exonuclease analysis revealed
several
strong and weak stops within the STAT and UBP sites. Analysis
of control genomic DNA also revealed strong sequence-dependent
stops,
making it difficult to definitively attribute the weaker
stops to
chromatin-dependent pausing of the exonuclease. The exonuclease
assay seems to specifically detect C/EBP and OctI binding. However,
exonuclease stops are present in chromatin from nuclei isolated
from
actively growing cells (growth) as well as in cells cultured
in the
presence or absence of ECM and/or prolactin (i.e., IH versus
IHP).
Despite the strong transcriptional induction by ECM and prolactin, no
differences were observed in the binding of nuclear
proteins to the
functionally important regions of BCE-1, in vitro.
Furthermore, while
only C/EBP could definitively be shown to bind
in vivo, there were no
differences with or without ECM. We therefore
wished to determine
whether ECM and/or prolactin could induce
transcription via the BCE-1
enhancer on a nonintegrated template
in a transient-transfection assay.
ECM and prolactin do not induce transcriptional activation of
transiently transfected templates.
We examined the transcriptional
activity of several chimeric constructs in transient-transfection
assays. When integrated into the genome, these constructs respond
either positively or negatively to the presence of ECM (37a,
45). In these experiments, the mouse mammary tumor virus (MMTV)
and simian virus 40 (SV40) enhancers were linked to the bovine
-casein promoter or the minimal (
110) MMTV promoter (Fig.
5C). The grid shown in Fig. 5C summarizes the results from the transient-transfection assays performed with these
constructs, as well as the activities of these same constructs when
stably integrated. ECM did not induce BCE-1-dependent transcription on
a transient template (no detectable CAT activity), even though endogenous
-casein was differentially expressed under these culture conditions, as shown by the immunoprecipitation of mouse milk proteins
from parallel plates of transfected cells (Fig. 5A). To address the
question of whether the basal
-casein promoter is capable of
supporting transient transcription, the promoter was linked to the SV40
enhancer. This construct had transient transcriptional activity (Fig.
5C). This result clearly demonstrates that the absence of transcription
after transient transfection of BCE-1 constructs and treatment of cells
with ECM was not due to the failure to utilize the
-casein promoter.
The requirement for stable integration of BCE-1 is striking. We
therefore decided to examine whether alterations in the chromatin
structure of the integrated BCE-1 element could influence
transcriptional activity. Because of the strong correlation between
histone acetylation and gene activation (33, 55, 60), we
analyzed the effect of histone modification on ECM-induced
transcription.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
ECM does not induce transcriptional activation of
nonintegrated templates in transient-transfection analysis. (A)
Autoradiograph of an immunoprecipitation reaction using an antibody to
mouse milk. The 35S-labeled proteins were precipitated from
parallel plates of transiently transfected cells cultured on plastic or
low-density polyhema treated with 2% ECM. (B) A representative
autoradiograph of a CAT assay. Ten micrograms of protein from cell
lysates isolated from CID-9 cells transiently transfected with BBC or
RSV/CAT while cultured on plastic (P) or low-density polyhema treated
with 2% ECM (E) was analyzed. (C) A diagram for each plasmid tested in
the transient-transfection analysis is shown to the left. BCE-1,
-casein, and MMTV are labeled relative to the transcription start
site of the endogenous genes. The seven constructs contained the
reporter CAT gene. The adjacent table represents the activity of each
construct when transiently or stably transfected into CID-9 cells and
differentiated in IHP on plastic or ECM as described in Materials and
Methods. The transient activity is relative to cotransfected
RSV- -Gal expression (a promoter which is not regulated by the
presence of ECM). , no detectable activity; +, increasing amounts of
transcriptional activity. These data represent at least three
independent transfections for each condition.
|
|
Inhibitors of histone deacetylase induce BCE-1-mediated
transcription in the absence of ECM.
Stably transfected CID-9
cells cultured on tissue culture plastic or ECM were treated with
sodium butyrate, an inhibitor of histone deacetylase. Treatment
with sodium butyrate is capable of inducing transcription to levels
achieved in the presence of ECM (Fig.
6A). The induction of transcription by
sodium butyrate was reproducible with differences in the absolute fold
increase in the absence of ECM. (Figure 6B shows a representative CAT
TLC and a graph of the quantitated results.) However, in the presence of ECM, when transcription is high, the transcriptional induction by
sodium butyrate was always equal to or less than twofold (Fig. 6A and
data not shown). Since sodium butyrate treatment has been shown to
induce many changes in the cell in addition to the inhibition of
histone deacetylase (18, 24, 27, 40), we tested a more specific inhibitor of histone deacetylase, trichostatin A
(62). A dose-dependent induction of transcription of up to
10-fold was observed in cells cultured with trichostatin A in the
absence of ECM (Fig. 6C) which, as with sodium butyrate, achieved
levels similar to that of the ECM induction and induced ECM levels less than twofold (data not shown). To determine whether sodium butyrate and
trichostatin A activation was due to a generalized increase in cellular
transcription, we analyzed the ECM-responsive MMTV promoter in stably
transfected CID-9 cells under the same culture conditions and
treatments. The presence of sodium butyrate, as well as of trichostatin
A, led to a dose-dependent repression of MMTV transcription either in
the absence (Fig. 7A and C) or in the
presence (Fig. 7B and D) of ECM. The activation of BCE-1 and the
inactivation of MMTV through inhibition of histone deacetylase suggest
that ECM-dependent transcription may involve alterations in the
acetylation state of the histones.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 6.
Treatment of CID-9 cells with histone deacetylase
inhibitors induces transcription in the absence of ECM in stable BBC
transfectants. (A) CID-9 cells were cultured on plastic or ECM and
treated with various doses of sodium butyrate. Cell lysates were
assayed for CAT activity, and the graph represents the densities
relative to those of the cells on plastic with no treatment. (B and C)
Representatives of at least three independent experiments where stably
BBC-transfected CID-9 cells were plated on plastic in the presence of
differentiation medium for 2 days before harvest. Sodium butyrate or
trichostatin A was added 18 h before harvest. The autoradiograph
shows a TLC separation of the CAT reaction products, utilizing 10 µg
of protein from cell lysates for the assay. The graph represents
density per microgram of protein per minute of CAT reaction. (The
treatments described above will induce BBC activity in cells cultured
on ECM by about twofold; data not shown.)
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 7.
Treatment of CID-9 cells with histone deacetylase
inhibitors has opposing effects on the stable MMTV transfectants.
Representative results from one of at least three experiments where
stable MMTV LTR transfectants were plated on plastic or ECM in
differentiation medium. The cells were cultured and treated with sodium
butyrate (A and B) or with trichostatin A (C and D) as described for
Fig. 6. The data is expressed as units of luciferase activity per
microgram of protein.
|
|
 |
DISCUSSION |
In this paper we show that transcriptional activation of
-casein, via the BCE-1 enhancer, requires that the ECM and prolactin coordinate the interactions between at least three transcription factors and the chromosomally integrated template containing BCE-1. Furthermore, BCE-1 transcriptional activation can be induced in the
absence of ECM upon treatment of stably transfected CID-9 cells with
inhibitors of histone deacetylase.
Mutation of any of three regions within BCE-1 abolishes ECM- and
prolactin-induced transcription, suggesting a cooperative interplay
between the factors that bind to these sites. Our analyses indicate
that C/EBP
, STAT5, and an additional but as-yet-unknown protein
(i.e., the UBP) recognize these sites. Several laboratories have
demonstrated the requirement for both STAT and C/EBP for hormone-induced
-casein expression. Standke et al. (49)
have shown that truncation of the rat
-casein promoter, which
removes C/EBP binding sites and leaves only the STAT site, abolishes
induction of
-casein transcription. Doppler et al. (16)
have shown by truncation analysis that both the C/EBP and STAT sites of
the rat
-casein promoter are required for activation of a
heterologous thymidine kinase promoter. Taken together, these
experiments suggest that the induction of
-casein expression
minimally requires the interplay of C/EBP and STAT and, in the case of
BCE-1, the UBP.
The ECM, in which laminin has been shown to be the active component,
induces
-casein gene expression requiring each of the following: a
rounded cell shape (42), signal transduction via laminin
binding and ligating of a
1-containing integrin (52), prolactin, integration into the genome, and a promoter which contains intact binding sites for C/EBP, STAT5, and the UBP. Furthermore, ECM-induced
-casein expression may require a modulation of the state
of histone acetylation. However, the ECM does not appear to modulate
the levels or binding activities of nuclear proteins specific to the
C/EBP, STAT5, and UBP binding sites. In vitro EMSA and in vivo
exonuclease footprinting analysis (in the case of C/EBP) indicate that
these factors are present and able to bind DNA in the absence of ECM.
This is in contrast to the ECM-dependent induction of albumin
expression in hepatocytes, where liver-specific gene transcription
appears to depend on the presence of liver-enriched transcription
factors which are upregulated in hepatocytes cultured on ECM
(13).
The findings that STAT5 has binding activity (Fig. 3) and that a STAT5
reporter gene construct is activated to the same extent (data not
shown) whether CID9 cells were cultured under differentiation conditions or not differ from the results obtained by Streuli et al.
(51). Streuli et al. showed that nuclear extracts from primary mouse mammary epithelial cells cultured on ECM formed a
specific complex with a STAT5 binding site in the
-lactoglobulin promoter, whereas extracts from cells cultured on plastic did not. This
binding activity was maintained only in cells cultured on ECM in the
presence of prolactin. While it is possible that the binding of STAT5
differs for sheep
-lactoglobulin and bovine
-casein, another
explanation for this discrepancy could reside in differences between
primary and immortalized cells. The primary cells undoubtedly have
complex requirements for induction of expression of tissue-specific
genes which may be relaxed or altered in cell lines. Indeed the
homolog, STAT5b, is able to activate transcription of the rat
-casein gene in COS cells cultured in the absence of prolactin
(32). Constitutively activated STAT5 has been observed in T
cells transformed with human T-cell leukemia virus type 1 (35) and in peripheral blood cells from patients with acute leukemia (21). In addition, STAT binding to the
interleukin-6 response element and the hematopoietin receptor
response element has been observed in the absence of
transcriptional activation (26). It is therefore plausible
that in immortalized CID-9 cells STAT5 could be present and
constitutively bound to BCE-1 in the absence of ECM. These cell lines
now make it possible to study the events subsequent to binding of STAT,
which would not be possible in primary cultures.
Thus, the experiments we report here lead us to conclude that the
binding of STAT5 is not sufficient to activate transcription of the
BCE-1 enhancer in the absence of ECM and prolactin. The fact that the
other factors also appear to be bound in the absence of ECM indicates
that the transcriptional activation is not solely due to the binding of
individual transcription factors. Rather, a proper structural signal
may be required for the activation of preassembled transcriptional
machinery which is poised for rapid transcription. This observation has
a precedent in the literature: in vivo footprinting analysis reveals
that the occupancy of the sites in the serum response element of the
fos promoter remains unchanged regardless of the
transcriptional state of the gene (22). In that study the
authors proposed and subsequently showed (64) that
activation and inactivation may be brought about by modifications to
the proteins in the bound complex or by interactions between the
complex and additional factors. The continuous occupancy of the serum
response element may be a mechanism for achieving a rapid activation as
maximal fos transcription occurs less than 20 min after
growth factor addition. Although
-casein is not considered a
rapid-response gene, it is conceivable that committed mammary
epithelial cells have been organized in vivo to respond rapidly to
conditions that modulate milk protein gene expression. Therefore, it
would be interesting to determine the occupancy of factors bound to
BCE-1 in nonmammary epithelial cells.
In vitro factor binding analyses indicate that the factors which are
critical for transcriptional activation via BCE-1 are present and are
capable of binding in both the transcriptionally active and inactive
states. Although factor binding does not address the functionality of
proteins bound to the DNA or whether the composition of the bound
complex has changed, the lack of response to ECM by nonintegrated BCE-1
constructs suggests that modifications of trans-acting
factors by ECM or changes in the complex composition are not sufficient
to account for the enhancer's function and that modifications within
the context of chromatin are necessary. Cell type-specific chromatin
arrangements mediated via cell-specific factors have been described for
the liver-specific albumin gene in hepatocytes (34). The
albumin enhancer exists in an array of three positioned nucleosomes
only in hepatocytes, and this positioning is dependent upon binding of
a liver-enriched nuclear factor, HNF3.
Chromatin alterations which lead to induction of gene expression may be
achieved through any or all of the following: modifications of
histones, changes in DNA conformation, factor accessibility, and DNA
and/or nuclear factor localization (for general reviews, see references
17 and 23). The fact that
integrated BCE-1 is activated in the absence of ECM upon treatment with
inhibitors of histone deacetylase suggests that a component of
ECM-dependent
-casein expression involves histone modifications,
which are believed to be involved in the transcriptional regulation of
genes (reviewed in references 33,
55, and 60). One possible
mechanism involves ECM-induced changes in the three-dimensional
architecture of the cell, influencing in turn the three-dimensional
architecture of the nucleus. Alterations in the structure or
composition of the nuclear matrix may reposition histone
acetyltransferases and/or deacetylases, which are known to be bound to
the nuclear scaffolding (9). The changes in protein-nuclear
scaffold and/or protein-DNA interactions involved in this nuclear
reorganization may result in the activation of the
-casein gene
following a more direct change in the modification state of the
histones (see reference 4 and references therein for
hypothesis). Another possibility is that the ECM induces or modifies
cofactors which themselves have acetyltransferase or deacetylase
activity. Recent characterization of novel histone acetyltransferases
includes p300/CBP-associated factor (61). The
transcriptional coactivator p300 (38) and TAFII250
(37) suggest potential targets which could be involved in
ECM-induced transcription. Interestingly, p300 directly interacts with
C/EBP
to increase transcriptional activity (36) and also interacts with the transcriptional repressor YY1 to relieve YY1 repression (28). These findings are consistent with the
current understanding of mechanisms underlying the transcriptional
regulation of
-casein.
Although factor availability and modification of DNA accessibility of
C/EBP do not account for ECM-dependent activation of the BCE-1 element,
it is clear that complex interactions between several factors on a
chromosomally integrated template are involved. Whether the
ECM-induced changes in higher-order chromatin structures are
mediated via alterations in nuclear architecture and/or ECM induces
cofactors which modulate the modification of the state of histones is
currently under investigation.
 |
ACKNOWLEDGMENTS |
We are grateful to Steve Farmer for providing the protocol for
ECM dissolution, Lothar Henninghausen for the STAT5a STAT5b antibodies,
and Wolfgang Doppler for helpful scientific discussions. We thank Paul
Kaufman, Judy Campisi, Nancy Boudreau, and Niveen Malek for critically
reading the manuscript.
C. Schmidhauser and R. Mossi were partly supported by the Swiss Cancer
League. A majority of this work was supported by the office of Health
and Environmental Research of the U.S. Department of Energy (under
contract number DE-AC03-SF00098 to M.J.B.). This work was also
supported by a gift from Monsanto Company and a grant from the
U.S.-Israel Binational Agricultural Research and Development Fund (BARD
project no. IS-2373-94R) to M.J.B.
 |
FOOTNOTES |
*
Corresponding author. Berkeley National Laboratory,
Life Sciences Division, 1 Cyclotron Rd., Bldg. 83-101, Berkeley, CA
94720. Phone: (510) 486-4365. Fax: (510) 486-5586. E-mail:
mjbissell{at}lbl.gov.
 |
REFERENCES |
| 1.
|
Adams, J. C., and F. M. Watt.
1993.
Regulation of development and differentiation by the extracellular matrix.
Development
117:1183-1198[Medline].
|
| 2.
|
Barcellos-Hoff, M. H.,
J. Aggeler,
T. G. Ram, and M. J. Bissell.
1989.
Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane.
Development
105:223-235[Abstract].
|
| 3.
|
Bissell, M. J., and H. G. Hall.
1987.
The role of extracellular matrix, p. 97-146. In
M. Nevelle, and C. Daniel (ed.), The mammary gland.
Plenum Press, New York, N.Y.
|
| 4.
|
Boudreau, N. J.,
C. A. Myers, and M. J. Bissell.
1995.
From laminin to lamin: regulation of tissue-specific gene expression by the ECM.
Trends Cell Biol.
5:1-4.
[Medline] |
| 5.
|
Burdon, T. G.,
J. Demmer,
A. J. Clark, and C. J. Watson.
1994.
The mammary factor MPBF is a prolactin-induced transcriptional regulator which binds to STAT factor recognition sites.
FEBS Lett.
350:177-182[Medline].
|
| 6.
|
Burdon, T. G.,
K. A. Maitland,
A. J. Clark,
R. Wallace, and C. J. Watson.
1994.
Regulation of the sheep beta-lactoglobulin gene by lactogenic hormones is mediated by a transcription factor that binds an interferon-gamma activation site-related element.
Mol. Endocrinol.
8:1528-1536[Abstract/Free Full Text].
|
| 7.
|
Cao, Z.,
R. M. Umek, and S. L. McKnight.
1991.
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
Genes Dev.
5:1538-1552[Abstract/Free Full Text].
|
| 8.
|
Danielson, K. G.,
C. J. Oborn,
E. M. Durban,
J. S. Buetel, and D. Medina.
1984.
Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro.
Proc. Natl. Acad. Sci. USA
81:3756-3760[Abstract/Free Full Text].
|
| 9.
|
Davie, J. R.
1996.
Histone modifications, chromatin structure, and the nuclear matrix.
J. Cell. Biochem.
62:149-157[Medline].
|
| 10.
|
Deryckere, F., and F. Gannon.
1994.
A one-hour minipreparation technique for extraction of DNA-binding proteins from animal tissues.
BioTechniques
16:405.
[Medline] |
| 11.
|
Desprez, P.,
C. D. Roskelley,
J. Campisi, and M. J. Bissell.
1993.
Isolation of functional cell lines from a mouse mammary epithelial cell strain: the importance of basement membrane and cell-cell interaction.
Mol. Cell. Differ.
1:99-110.
|
| 12.
|
de Wet, J. R.,
K. V. Wood,
M. DeLuca,
D. R. Helinski, and S. Subramani.
1987.
Firefly luciferase gene: structure and expression in mammalian cells.
Mol. Cell. Biol.
7:725-737[Abstract/Free Full Text].
|
| 13.
|
DiPersio, C. M.,
D. A. Jackson, and K. S. Zaret.
1991.
The extracellular matrix coordinately modulates liver transcription factors and hepatocyte morphology.
Mol. Cell. Biol.
11:4405-4414[Abstract/Free Full Text].
|
| 14.
|
Doppler, W.,
B. Groner, and R. K. Ball.
1989.
Prolactin and glucocorticoid hormones synergistically induce expression of transfected rat beta-casein gene promoter constructs in a mammary epithelial cell line.
Proc. Natl. Acad. Sci. USA
86:104-108[Abstract/Free Full Text].
|
| 15.
|
Doppler, W.,
W. Hock,
P. Hofer,
B. Groner, and R. K. Ball.
1990.
Prolactin and glucocorticoid hormones control transcription of the beta-casein gene by kinetically distinct mechanisms.
Mol. Endocrinol.
4:912-919[Abstract/Free Full Text].
|
| 16.
|
Doppler, W.,
T. Welte, and S. Philipp.
1995.
CCAAT/enhancer-binding protein isoforms beta and delta are expressed in mammary epithelial cells and bind to multiple sites in the beta-casein gene promoter.
J. Biol. Chem.
270:17962-17969[Abstract/Free Full Text].
|
| 17.
|
Felsenfeld, G.
1996.
Chromatin unfolds.
Cell
86:13-19[Medline].
|
| 18.
|
Ginsburg, E.,
D. Salomon,
T. Sreevalsan, and E. Freese.
1973.
Growth inhibition and morphological changes caused by lipophilic acids in mammalian cells.
Proc. Natl. Acad. Sci. USA
70:2457-2461[Abstract/Free Full Text].
|
| 19.
|
Goodman, H. S., and J. M. Rosen.
1990.
Transcriptional analysis of the mouse beta-casein gene.
Mol. Endocrinol.
4:1661-1670[Abstract/Free Full Text].
|
| 20.
|
Gouilleux, F.,
H. Wakao,
M. Mundt, and B. Groner.
1994.
Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription.
EMBO J.
13:4361-4369[Medline].
|
| 21.
|
Gouilleux-Gruart, V.,
F. Gouilleux,
C. Desaint,
J. F. Claisse,
J. C. Capiod,
J. Delobel,
R. Weber-Nordt,
I. Dusanter-Fourt,
F. Dreyfus,
B. Groner, and L. Prin.
1996.
STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.
Blood
87:1692-1697[Abstract/Free Full Text].
|
| 22.
|
Herrera, R. E.,
P. E. Shaw, and A. Nordheim.
1989.
Occupation of the c-fos serum response element in vivo by a multi-protein complex is unaltered by growth factor induction.
Nature
340:68-70[Medline].
|
| 23.
|
Kingston, R. E.,
C. A. Bunker, and A. N. Imbalzano.
1996.
Repression and activation by multiprotein complexes that alter chromatin structure.
Genes Dev.
10:905-920[Abstract/Free Full Text].
|
| 24.
|
Kruh, J.
1982.
Effects of sodium butyrate, a new pharmacological agent, on cells in culture.
Mol. Cell. Biochem.
42:65-82[Medline].
|
| 25.
|
Kulski, J. K.,
Y. J. Topper,
P. Chomczynski, and P. Qasba.
1983.
An essential role for glucocorticoid in casein gene expression in rat mammary explants.
Biochem. Biophys. Res. Commun.
114:380-387[Medline].
|
| 26.
|
Lai, C. F.,
J. Ripperger,
K. K. Morella,
Y. Wang,
D. P. Gearing,
G. H. Fey, and H. Bauman.
1995.
Separate signaling mechanisms are involved in the control of STAT protein activation and gene regulation via interlurkin 6 response element by the box 3 motif of gp130.
J. Biol. Chem.
270:14847-14850[Abstract/Free Full Text].
|
| 27.
|
Leder, A., and P. Leder.
1975.
Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells.
Cell
5:319-322[Medline].
|
| 28.
|
Lee, J. S.,
K. M. Galvin,
R. H. See,
R. Eckner,
D. Livingston,
E. Moran, and Y. Shi.
1995.
Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300.
Genes Dev.
9:1188-1198[Abstract/Free Full Text].
|
| 29.
|
Lee, K. F.,
F. J. DeMayo,
S. H. Atiee, and J. M. Rosen.
1988.
Tissue-specific expression of the rat beta-casein gene in transgenic mice.
Nucleic Acids Res.
16:1027-1041[Abstract/Free Full Text].
|
| 30.
|
Lee, P. P.,
M. T. Lee,
K. M. Darcy,
K. Shudo, and M. M. Ip.
1995.
Modulation of normal mammary epithelial cell proliferation, morphogenesis, and functional differentiation by retinoids: a comparison of the retinobenzoic acid derivative RE80 with retinoic acid.
Endocrinology
136:1707-1717[Abstract].
|
| 31.
|
LeFebvre, P.,
D. S. Berard,
M. G. Cordingley, and G. L. Hager.
1991.
Two regions of the mouse mammary tumor virus long terminal repeat regulate the activity of its promoter in mammary cell lines.
Mol. Cell. Biol.
11:2529-2537[Abstract/Free Full Text].
|
| 32.
|
Liu, X.,
G. Robinson,
F. Gouilleux,
B. Groner, and L. Hennighausen.
1995.
Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue.
Proc. Natl. Acad. Sci. USA
92:8831-8835[Abstract/Free Full Text].
|
| 33.
|
Loidl, P.
1994.
Histone acetylation: facts and questions.
Chromosoma
103:441-449[Medline].
|
| 34.
|
McPherson, C. E.,
E. Y. Shim,
D. S. Friedman, and K. S. Zaret.
1993.
An active tissue-specific enhancer and bound transcription factors existing in a precisely positioned nucleosomal array.
Cell
75:387-398[Medline].
|
| 34a.
| Michelotti, J. Unpublished data.
|
| 35.
|
Migone, T. S.,
J. X. Lin,
A. Cereseto,
J. C. Mulloy,
J. J. O'Shea,
G. Franchini, and W. J. Leonard.
1995.
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.
Science
269:79-81[Abstract/Free Full Text].
|
| 36.
|
Mink, S.,
B. Haenig,
K. H. Klempnauer, and H. Spemann.
1997.
Interaction and functional collaboration of p300 and C/EBP .
Mol. Cell. Biol.
11:6609-6617.
|
| 37.
|
Mizzen, C. A.,
X. Yang,
T. Kokubo,
J. E. Brownell,
A. J. Bannister,
T. Owen-Huges,
J. Workman,
L. Wang,
S. L. Berger,
T. Kouzarides,
Y. Nakatani, and C. D. Allis.
1996.
The TAFII250 subunit of TFIID has histone acetyltransferase activity.
Cell
87:1261-1270[Medline].
|
| 37a.
| Myers, C., and J. Michelotti. Unpublished data.
|
| 38.
|
Ogryzko, V. V.,
R. L. Schiltz,
V. Russanova,
B. H. Howard, and Y. Nakatani.
1996.
The transcriptional coactivators p300 and CBP are histone acetyltransferases.
Cell
5:953-959.
|
| 39.
|
Pennie, W. D.,
G. L. Hager, and C. L. Smith.
1995.
Nucleoprotein structure influences the response of the mouse mammary tumor virus promoter to activation of the cyclic AMP signalling pathway.
Mol. Cell. Biol.
15:2125-2134[Abstract].
|
| 40.
|
Prasad, K. N., and P. K. Sinha.
1976.
Effect of sodium butyrate on mammalian cells in culture: a review.
In Vitro
12:125-132[Medline].
|
| 41.
|
Raught, B.,
W. S. Liao, and J. M. Rosen.
1995.
Developmentally and hormonally regulated CCAAT/enhancer-binding protein isoforms influence beta-casein gene expression.
Mol. Endocrinol.
9:1223-1232[Abstract/Free Full Text].
|
| 42.
|
Roskelley, C. D.,
P. Y. Desprez, and M. J. Bissell.
1994.
Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction.
Proc. Natl. Acad. Sci. USA
91:12378-12382[Abstract/Free Full Text].
|
| 43.
|
Roskelley, C. D.,
A. Srebrow, and M. J. Bissell.
1995.
A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression.
Curr. Opin. Cell Biol.
7:736-747[Medline].
|
| 44.
|
Schmidhauser, C.,
M. J. Bissell,
C. A. Myers, and G. F. Casperson.
1990.
Extracellular matrix and hormones transcriptionally regulate bovine beta-casein 5' sequences in stably transfected mouse mammary cells.
Proc. Natl. Acad. Sci. USA
87:9118-9122[Abstract/Free Full Text].
|
| 45.
|
Schmidhauser, C.,
G. F. Casperson, and M. J. Bissell.
1994.
Transcriptional activation by viral enhancers: critical dependence on extracellular matrix-cell interactions in mammary epithelial cells.
Mol. Carcinog.
10:66-71[Medline].
|
| 46.
|
Schmidhauser, C.,
G. F. Casperson,
C. A. Myers,
K. T. Sanzo,
S. Bolten, and M. J. Bissell.
1992.
A novel transcriptional enhancer is involved in the prolactin- and extracellular matrix-dependent regulation of beta-casein gene expression.
Mol. Biol. Cell
3:699-709[Abstract].
|
| 47.
|
Schmitt-Ney, M.,
W. Doppler,
R. K. Ball, and B. Groner.
1991.
Beta-casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor.
Mol. Cell. Biol.
11:3745-3755[Abstract/Free Full Text].
|
| 48.
|
Shapiro, D. J.,
P. A. Sharp,
W. W. Wahli, and M. J. Keller.
1988.
A high-efficiency HeLa cell nuclear transcription extract.
DNA
7:47-55[Medline].
|
| 49.
|
Standke, G. J.,
V. S. Meier, and B. Groner.
1994.
Mammary gland factor activated by prolactin on mammary epithelial cells and acute-phase response factor activated by interleukin-6 in liver cells share DNA binding and transactivation potential.
Mol. Endocrinol.
8:469-477[Abstract/Free Full Text].
|
| 50.
|
Stocklin, E.,
M. Wissler,
F. Gouilleux, and B. Groner.
1996.
Functional interactions between Stat 5 and the glucocorticoid receptor.
Nature
383:726-728[Medline].
|
| 51.
|
Streuli, C. H.,
G. M. Edwards,
M. Delcommenne,
C. B. Whitelaw,
T. G. Burdon,
C. Schindler, and C. J. Watson.
1995.
Stat5 as a target for regulation by extracellular matrix.
J. Biol. Chem.
270:21639-21644[Abstract/Free Full Text].
|
| 52.
|
Streuli, C. H.,
C. Schmidhauser,
N. Bailey,
P. Yurchenco,
A. P. Skubitz,
C. Roskelley, and M. J. Bissell.
1995.
Laminin mediates tissue-specific gene expression in mammary epithelia.
J. Cell Biol.
129:591-603[Abstract/Free Full Text].
|
| 53.
|
Taketani, Y., and T. Oka.
1983.
Tumor promoter 12-O-tetradecanoylphorbol 13-acetate, like epidermal growth factor, stimulates cell proliferation and inhibits differentiation of mouse mammary epithelial cells in culture.
Proc. Natl. Acad. Sci. USA
80:1646-1649[Abstract/Free Full Text].
|
| 54.
|
Topper, Y. J., and C. S. Freeman.
1980.
Multiple hormone interactions in the developmental biology of the mammary gland.
Physiol. Rev.
60:1049-1106[Free Full Text].
|
| 55.
|
Turner, B. M., and L. P. O'Neill.
1995.
Histone acetylation in chromatin and chromosomes.
Semin. Cell Biol.
6:229-236[Medline].
|
| 56.
|
Wakao, H.,
F. Gouilleux, and B. Groner.
1994.
Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response.
EMBO J.
13:2182-2191[Medline]. (Erratum, 14:854-855, 1995.)
|
| 57.
|
Wakao, H.,
F. Gouilleux, and B. Groner.
1995.
Mammary gland factor (MGF) is a novel member of the cytokine regulated transcription factor gene family and confers the prolactin response.
EMBO J.
14:854-855[Medline].
|
| 58.
|
Watson, C. J.,
K. E. Gordon,
M. Robertson, and A. J. Clark.
1991.
Interaction of DNA-binding proteins with a milk protein gene promoter in vitro: identification of a mammary gland-specific factor.
Nucleic Acids Res.
19:6603-6610[Abstract/Free Full Text].
|
| 59.
|
Welte, T.,
K. Garimorth,
S. Philipp, and W. Doppler.
1994.
Prolactin-dependent activation of a tyrosine phosphorylated DNA binding factor in mouse mammary epithelial cells.
Mol. Endocrinol.
8:1091-1102[Abstract/Free Full Text].
|
| 60.
|
Wolffe, A. P.
1996.
Histone deacetylase: a regulator of transcription.
Science
272:371-372[Medline].
|
| 61.
|
Yang, X. J.,
B. H. Howard, and Y. Nakatani.
1996.
A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A.
Nature
382:319-324[Medline].
|
| 62.
|
Yoshida, M.,
M. Kijima,
M. Akita, and T. Beppu.
1990.
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A.
J. Biol. Chem.
265:17174-17179[Abstract/Free Full Text].
|
| 63.
|
Yoshimura, M., and T. Oka.
1990.
Transfection of beta-casein chimeric gene and hormonal induction of its expression in primary murine mammary epithelial cells.
Proc. Natl. Acad. Sci. USA
87:3670-3674[Abstract/Free Full Text].
|
| 64.
|
Zinck, R.,
R. A. Hipskind,
V. Pingoud, and A. Nordheim.
1993.
c-fos transcriptional activation and repression correlate temporally with the phosphorylation status of TCF.
EMBO J.
12:2377-2387[Medline].
|
Mol Cell Biol, April 1998, p. 2184-2195, Vol. 18, No. 4
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Xu, R., Spencer, V. A., Bissell, M. J.
(2007). Extracellular Matrix-regulated Gene Expression Requires Cooperation of SWI/SNF and Transcription Factors. J. Biol. Chem.
282: 14992-14999
[Abstract]
[Full Text]
-
Sandal, T., Valyi-Nagy, K., Spencer, V. A., Folberg, R., Bissell, M. J., Maniotis, A. J.
(2007). Epigenetic Reversion of Breast Carcinoma Phenotype Is Accompanied by Changes in DNA Sequestration as Measured by AluI Restriction Enzyme. Am. J. Pathol.
170: 1739-1749
[Abstract]
[Full Text]
-
Leslie, M.
(2006). ECM determines fate. JCB
173: 6a-7
[Full Text]
-
Maniotis, A. J., Valyi-Nagy, K., Karavitis, J., Moses, J., Boddipali, V., Wang, Y., Nunez, R., Setty, S., Arbieva, Z., Bissell, M. J., Folberg, R.
(2005). Chromatin Organization Measured by AluI Restriction Enzyme Changes with Malignancy and Is Regulated by the Extracellular Matrix and the Cytoskeleton. Am. J. Pathol.
166: 1187-1203
[Abstract]
[Full Text]
-
BISSELL, M.J., KENNY, P.A., RADISKY, D.C.
(2005). Microenvironmental Regulators of Tissue Structure and Function Also Regulate Tumor Induction and Progression: The Role of Extracellular Matrix and Its Degrading Enzymes. Cold Spring Harb Symp Quant Biol
70: 343-356
[Abstract]
-
Zoubiane, G. S., Valentijn, A., Lowe, E. T., Akhtar, N., Bagley, S., Gilmore, A. P., Streuli, C. H.
(2004). A role for the cytoskeleton in prolactin-dependent mammary epithelial cell differentiation. J. Cell Sci.
117: 271-280
[Abstract]
[Full Text]
-
Novaro, V., Roskelley, C. D., Bissell, M. J.
(2003). Collagen-IV and laminin-1 regulate estrogen receptor {alpha} expression and function in mouse mammary epithelial cells. J. Cell Sci.
116: 2975-2986
[Abstract]
[Full Text]
-
Chua, Y. L., Watson, L. A., Gray, J. C.
(2003). The Transcriptional Enhancer of the Pea Plastocyanin Gene Associates with the Nuclear Matrix and Regulates Gene Expression through Histone Acetylation. Plant Cell
15: 1468-1479
[Abstract]
[Full Text]
-
Woodward, T. L., Mienaltowski, A. S., Modi, R. R., Bennett, J. M., Haslam, S. Z.
(2001). Fibronectin and the {{alpha}}5{beta}1 Integrin Are Under Developmental and Ovarian Steroid Regulation in the Normal Mouse Mammary Gland. Endocrinology
142: 3214-3222
[Abstract]
[Full Text]
-
Deckert, J., Struhl, K.
(2001). Histone Acetylation at Promoters Is Differentially Affected by Specific Activators and Repressors. Mol. Cell. Biol.
21: 2726-2735
[Abstract]
[Full Text]
-
Yang, L., Guerrero, J., Hong, H., DeFranco, D. B., Stallcup, M. R.
(2000). Interaction of the tau 2 Transcriptional Activation Domain of Glucocorticoid Receptor with a Novel Steroid Receptor Coactivator, Hic-5, Which Localizes to Both Focal Adhesions and the Nuclear Matrix. Mol. Biol. Cell
11: 2007-2018
[Abstract]
[Full Text]
-
Vanden Berghe, W., De Bosscher, K., Boone, E., Plaisance, S., Haegeman, G.
(1999). The Nuclear Factor-kappa B Engages CBP/p300 and Histone Acetyltransferase Activity for Transcriptional Activation of the Interleukin-6 Gene Promoter. J. Biol. Chem.
274: 32091-32098
[Abstract]
[Full Text]
-
Bissell, M. J.
(1999). Tumor Plasticity Allows Vasculogenic Mimicry, a Novel Form of Angiogenic Switch : A Rose by Any Other Name?. Am. J. Pathol.
155: 675-679
[Full Text]
-
Jones, P., Jones, F., Zhou, B, Rabinovitch, M
(1999). Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J. Cell Sci.
112: 435-445
[Abstract]
-
Lelievre, S. A., Weaver, V. M., Nickerson, J. A., Larabell, C. A., Bhaumik, A., Petersen, O. W., Bissell, M. J.
(1998). Tissue phenotype depends on reciprocal interactions between the extracellular matrix and the structural organization of the nucleus. Proc. Natl. Acad. Sci. USA
95: 14711-14716
[Abstract]
[Full Text]
-
Bhakat, K. K., Mitra, S.
(2000). Regulation of the Human O6-Methylguanine-DNA Methyltransferase Gene by Transcriptional Coactivators cAMP Response Element-binding Protein-binding Protein and p300. J. Biol. Chem.
275: 34197-34204
[Abstract]
[Full Text]